Skip to main content

Table 1 ACPA fine-specificities in anti-CCP2+ and anti-CCP- RA and controls

From: Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity

ACPA fine-specificities

Antibody frequencies (%)

Antibody levels (median)a

CCP2+

CCP2−

Controls

p valueb

CCP2+

CCP2−

p valuec

Cit-Fibß60–74

80.6

9.5

0.8

< 0.0001

195.3

27.1

< 0.0001

Cit-peptide-5

75.4

8.6

1.1

< 0.0001

81.4

27.2

< 0.0001

Cit-peptide-Z1

69.3

5.1

0.5

0.0001

167.4

38.6

< 0.0001

Cit-Fibß36–52

65.6

5.0

1.4

0.003

605.0

186.4

< 0.0001

Cit-Vim60–75

63.5

2.9

1.1

0.049

641.6

321.9

0.009

CEP-1

60.9

4.4

1.1

0.003

678.2

316.1

< 0.0001

cfc1-cyc (CCP1)

59.9

3.8

1.1

0.009

514.7

166.0

< 0.0001

Cit-Fibα563–583

57.6

2.5

1.1

0.10

444.8

144.0

0.002

Cit-peptide-Z2

49.5

2.9

0.3

0.003

150.9

58.6

0.002

Cit-peptide-1

45.0

4.7

1.9

0.02

72.7

29.2

< 0.0001

Cit-Fibα621–635

42.9

4.6

1.4

0.005

384.0

123.0

< 0.0001

Cit-peptide-Bla26

39.9

4.4

1.4

0.006

80.3

48.7

0.003

Cit-Vim2–17

40.3

2.6

1.4

0.16

75.9

72.8

0.712

Cit-F4(Cit-Cit)

36.1

3.4

1.6

0.08

84.9

60.6

0.032

Cit-F4(R-Cit)

29.9

2.1

1.4

0.36

86.4

80.6

0.366

Cit-Fibα580–600

24.2

2.8

1.4

0.11

264.2

197.2

0.024

Cit-Fibα36–50

17.6

4.0

1.9

0.053

422.9

265.5

< 0.0001

Cit-C1

10.8

1.9

1.4

0.48

69.3

87.9

0.383

Cit-F4(Cit-R)

6.2

1.8

1.1

0.34

403.0

306.5

0.382

  1. aMedian antibody levels are shown for ACPA+ patients only. P values indicate differences between banti-CCP2− RA and controls or between canti-CCP2+ and anti-CCP2− RA
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us